Fumagillin is a complex biomolecule and used as an antimicrobial agent. It was isolated in 1949 from the microbial organism Aspergillus fumigatus.[1]
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
ATC code | |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
DrugBank |
|
ChemSpider |
|
UNII |
|
ChEBI |
|
ChEMBL |
|
CompTox Dashboard (EPA) |
|
ECHA InfoCard | 100.041.288 |
Chemical and physical data | |
Formula | C26H34O7 |
Molar mass | 458.551 g·mol−1 |
3D model (JSmol) |
|
| |
| |
(what is this?) (verify) |
It was originally used against microsporidian parasites Nosema apis infections in honey bees.[citation needed]
Some studies found it to be effective against some myxozoan parasites, including Myxobolus cerebralis, an important parasite of fish; however, in the more rigorous tests required for U.S. Food and Drug Administration approval, it was ineffective.[citation needed]
There are reports that fumagillin controls Nosema ceranae,[2] which has recently been hypothesized as a possible cause of colony collapse disorder.[3][4] The latest report, however, has shown it to be ineffective against N. ceranae.[5] Fumagillin is also investigated as an inhibitor of malaria parasite growth.[6][7]
Fumagillin has been used in the treatment of microsporidiosis.[8][9] It is also an amebicide.[10]
Fumagillin can block blood vessel formation by binding to an enzyme methionine aminopeptidase 2[11] and for this reason, the compound, together with semisynthetic derivatives, are investigated as an angiogenesis inhibitor[12] in the treatment of cancer.
The company Zafgen conducted clinical trials using the fumagillin analog beloranib for weight loss,[13] but they were unsuccessful.[14]
Fumagillin is toxic to erythrocytes in vitro at concentrations greater than 10 μM.[15]
Fumagillin and the related fumagillol (the hydrolysis product) have been a target in total synthesis, with several reported successful strategies, racemic, asymmetric, and formal.[16][17][18][19][20][21][22][23][24]